- Home
- REFR vs ICCM Comparison
REFR vs ICCM Comparison
Compare REFR & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFR
- ICCM
- Stock Information
- Founded
- REFR 1965
- ICCM 2006
- Country
- REFR United States
- ICCM Israel
- Employees
- REFR N/A
- ICCM N/A
- Industry
- REFR Multi-Sector Companies
- ICCM
- Sector
- REFR Miscellaneous
- ICCM
- Exchange
- REFR Nasdaq
- ICCM Nasdaq
- Market Cap
- REFR 61.4M
- ICCM 61.1M
- IPO Year
- REFR N/A
- ICCM N/A
- Fundamental
- Price
- REFR $1.51
- ICCM $0.85
- Analyst Decision
- REFR
- ICCM Strong Buy
- Analyst Count
- REFR 0
- ICCM 1
- Target Price
- REFR N/A
- ICCM $2.50
- AVG Volume (30 Days)
- REFR 39.0K
- ICCM 2.6M
- Earning Date
- REFR 08-07-2025
- ICCM 08-13-2025
- Dividend Yield
- REFR N/A
- ICCM N/A
- EPS Growth
- REFR N/A
- ICCM N/A
- EPS
- REFR N/A
- ICCM N/A
- Revenue
- REFR $1,581,929.00
- ICCM $3,273,000.00
- Revenue This Year
- REFR N/A
- ICCM $75.27
- Revenue Next Year
- REFR N/A
- ICCM $129.39
- P/E Ratio
- REFR N/A
- ICCM N/A
- Revenue Growth
- REFR 62.28
- ICCM 0.34
- 52 Week Low
- REFR $0.93
- ICCM $0.48
- 52 Week High
- REFR $2.39
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- REFR 45.10
- ICCM 34.51
- Support Level
- REFR $1.52
- ICCM $0.87
- Resistance Level
- REFR $1.70
- ICCM $1.07
- Average True Range (ATR)
- REFR 0.14
- ICCM 0.06
- MACD
- REFR -0.02
- ICCM -0.02
- Stochastic Oscillator
- REFR 20.21
- ICCM 2.94
About REFR Research Frontiers Incorporated
Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light. The company develops and licenses its patented suspended particle device light-control technology to other companies that manufacture and market the SPD-Smart chemical emulsion, the light-control film made from the chemical emulsion, the light-control panels made by laminating the film, electronics to power end-products incorporating the film, or lamination services for, and the end-products. The company's revenue source comes from the licensing of technology.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.